Zacks: Analysts Expect Insulet Co. (NASDAQ:PODD) Will Post Quarterly Sales of $286.78 Million

Brokerages forecast that Insulet Co. (NASDAQ:PODDGet Rating) will announce sales of $286.78 million for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Insulet’s earnings. The highest sales estimate is $291.00 million and the lowest is $283.50 million. Insulet posted sales of $252.30 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 13.7%. The business is scheduled to announce its next quarterly earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Insulet will report full year sales of $1.24 billion for the current year, with estimates ranging from $1.23 billion to $1.26 billion. For the next year, analysts forecast that the company will post sales of $1.52 billion, with estimates ranging from $1.49 billion to $1.56 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Insulet.

Insulet (NASDAQ:PODDGet Rating) last posted its quarterly earnings data on Wednesday, February 23rd. The medical instruments supplier reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.12. The company had revenue of $307.70 million during the quarter, compared to analysts’ expectations of $300.57 million. Insulet had a net margin of 1.53% and a return on equity of 9.47%. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.26) EPS.

PODD has been the topic of a number of analyst reports. Piper Sandler cut their price target on Insulet from $295.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 24th. Oppenheimer upgraded shares of Insulet from a “market perform” rating to an “outperform” rating and reduced their price objective for the stock from $300.00 to $275.00 in a research note on Monday, January 31st. Morgan Stanley cut their target price on shares of Insulet from $300.00 to $268.00 and set an “equal weight” rating for the company in a research note on Friday, February 25th. Raymond James cut their target price on shares of Insulet from $329.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, February 24th. Finally, Zacks Investment Research downgraded shares of Insulet from a “hold” rating to a “strong sell” rating and set a $238.00 price objective for the company. in a research report on Monday, January 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $296.23.

NASDAQ:PODD traded up $1.03 on Wednesday, reaching $238.99. The stock had a trading volume of 633,425 shares, compared to its average volume of 349,949. The company has a 50-day moving average of $253.92 and a 200 day moving average of $265.39. The company has a current ratio of 5.81, a quick ratio of 4.49 and a debt-to-equity ratio of 2.24. The stock has a market cap of $16.57 billion, a P/E ratio of 1,039.09 and a beta of 0.67. Insulet has a 12-month low of $193.70 and a 12-month high of $324.81.

In other Insulet news, CEO Shacey Petrovic sold 15,000 shares of the business’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $273.25, for a total transaction of $4,098,750.00. Following the sale, the chief executive officer now owns 13,607 shares of the company’s stock, valued at $3,718,112.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Wayde D. Mcmillan sold 1,455 shares of the business’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $275.60, for a total transaction of $400,998.00. Following the sale, the chief financial officer now directly owns 21,354 shares in the company, valued at approximately $5,885,162.40. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

Several large investors have recently modified their holdings of the company. Mckinley Capital Management LLC Delaware acquired a new position in shares of Insulet during the first quarter worth $2,773,000. Park Avenue Securities LLC acquired a new position in Insulet in the first quarter valued at $211,000. FourThought Financial LLC acquired a new position in Insulet in the first quarter valued at $101,000. Daiwa Securities Group Inc. lifted its holdings in Insulet by 4.1% in the first quarter. Daiwa Securities Group Inc. now owns 5,305 shares of the medical instruments supplier’s stock valued at $1,413,000 after buying an additional 210 shares during the period. Finally, Krilogy Financial LLC acquired a new position in Insulet in the first quarter valued at $693,000.

Insulet Company Profile (Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Read More

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.